- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - AstraZeneca agrees to buy US FDA Priority Review
AnnouncementREG - AstraZeneca PLC - Roxadustat approved in China for the treatment of
AnnouncementREG - AstraZeneca PLC - Update on the Phase III NEPTUNE trial
AnnouncementREG - AstraZeneca PLC - Farxiga met primary endpoint in landmark Phase III
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Calquence granted US Breakthrough Therapy Designat
AnnouncementREG - AstraZeneca PLC - Lynparza Phase III PAOLA-1 trial met primary endpo
AnnouncementREG - AstraZeneca PLC - Amendment: Tagrisso significantly improves overall
AnnouncementREG - AstraZeneca PLC - Tagrisso significantly improves overall survival
AnnouncementREG - AstraZeneca PLC - Lynparza Phase III PROfound trial in HRR*
AnnouncementREG - AstraZeneca PLC - Forxiga label updated in the EU in type-2 diabetes
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AZN: H1 2019 Results
AnnouncementREG - AstraZeneca PLC - Update on US regulatory decision for Farxiga
AnnouncementREG - AstraZeneca PLC - Imfinzi granted US Orphan Drug Designation for
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Fasenra receives positive EU CHMP opinion for self
AnnouncementREG - AstraZeneca PLC - Forxiga receives positive EU CHMP opinion for
AnnouncementREG - AstraZeneca PLC - Imfinzi improves overall survival at interim
Announcement